Jabil Acquires Pharmaceutics International to Enhance Pharmaceutical Manufacturing Capabilities
- Jabil has acquired Pharmaceutics International, Inc. to enhance its pharmaceutical manufacturing capabilities, focusing on aseptic and sterile injectables.
- The acquisition aligns with Jabil's customer-centric approach, strengthening its offerings in formulation development and analytical services.
- Integrating Pii's expertise positions Jabil to capitalize on emerging opportunities in drug development and manufacturing within the healthcare sector.
Jabil Expands Capabilities with Acquisition of Pharmaceutics International, Inc.
In a strategic move to enhance its offerings in the pharmaceutical sector, Jabil Inc. has acquired Pharmaceutics International, Inc. (Pii) in an all-cash transaction. This acquisition, led by a consortium of investors including Signet Healthcare Partners, Athyrium Capital Management, Hildred Capital, and Pharmascience Inc., marks a significant development for Jabil as it seeks to bolster its presence in the manufacturing of aseptic and sterile injectable products. Pii, based in Hunt Valley, Maryland, has built a strong reputation over nearly three decades for its expertise in developing complex formulations and providing comprehensive services for both New Drug Applications (NDA) and abbreviated NDA (aNDA) products.
Pii’s operational model, which includes fee-for-service agreements and profit-sharing arrangements with marketing partners, aligns well with Jabil’s emphasis on innovative solutions and customer-centric approaches. The acquisition not only enhances Jabil's capabilities to support pharmaceutical companies with preformulation testing, formulation development, and commercial CGMP manufacturing but also strengthens its portfolio of analytical services. John Fowler, President and CEO of Pii, acknowledges the crucial role that the consortium's investors played in the company's growth, emphasizing their strategic insight in expanding Pii's capabilities and market reach. With advanced manufacturing suites and automated packaging lines, Pii is well-positioned to meet the increasing demand for high-quality pharmaceutical products.
The integration of Pii into Jabil's operations is expected to provide significant synergies, particularly in the areas of advanced manufacturing processes and innovative product developments. This acquisition comes at a time when the pharmaceutical industry is increasingly focusing on complex therapeutic solutions, and Jabil is poised to leverage Pii's expertise to enhance its service offerings. As Jabil continues to diversify its portfolio, this acquisition signifies a commitment to advancing its role in the healthcare sector while addressing the growing needs of pharmaceutical clients.
In addition to its manufacturing capabilities, Pii also provides a valuable platform for Jabil to engage in collaborative partnerships with various pharmaceutical companies. This strategic acquisition allows Jabil to establish a stronger foothold in the healthcare industry and positions the company to capitalize on emerging opportunities in drug development and manufacturing.
Legal counsel for the transaction was provided by Sidley Austin LLP, underscoring the importance of thorough legal oversight in significant corporate acquisitions. As Jabil integrates Pii's advanced capabilities, the company continues its trajectory towards becoming a leader in the healthcare manufacturing landscape.